BackgroundThe aim of this study was to investigate the discordance rates of eight known driver mutations among multiple matched intrapulmonary ground-glass nodules (GGNs) in non–small-cell lung cancer (NSCLC) patients.MethodsTumors from 35 patients with multiple lesions resected, including confirmed NSCLC and at least one GGN, were analyzed for mutations in EGFR, KRAS, HER2, BRAF, and PIK3CA together with fusions in ALK, ROS1, and RET.ResultsFrom 35 patients, a total of 72 lesions (60 were GGNs) were analyzed. These included nine adenocarcinoma in situ, nine minimal invasive adenocarcinoma, and 54 invasive adenocarcinoma. Among them, 33 tumor lesions (45.8 %) were found harboring EGFR mutations: 13 tumors with exon 19 deletion, 18 with L858...
BackgroundMany studies have examined specific mutations in patients with resected lung adenocarcinom...
Objective: Previous studies have indicated that EGFR exon 19 deletions in non-small cell lung cancer...
Discovery of driver mutations in pulmonary adenocarcinoma has revolutionized the field of thoracic o...
BackgroundThe aim of this study was to investigate the discordance rates of eight known driver mutat...
Objective: Synchronous multiple ground-glass nodules (SM-GGNs) are a distinct entity of lung cancer ...
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry add...
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is hi...
IntroductionNo standard guidelines detailing recommendations for the selection and treatment for mul...
Background: Reported prevalence of driver gene mutations in non-small cell lung cancer (NSCLC) is hi...
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is hi...
Background: Many studies have examined specific mutations in patients with resected lung adenocarcin...
Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variabl...
Background: KRAS, BRAF, EGFR and ALK-mutation testing is a prerequisite for non-small-cell lung canc...
Objective: Synchronous multiple ground-glass nodules (SM-GGNs) are a distinct entity of lung cancer ...
The prevalence of multiple lung cancers has been increasing recently. Molecular analysis of epiderma...
BackgroundMany studies have examined specific mutations in patients with resected lung adenocarcinom...
Objective: Previous studies have indicated that EGFR exon 19 deletions in non-small cell lung cancer...
Discovery of driver mutations in pulmonary adenocarcinoma has revolutionized the field of thoracic o...
BackgroundThe aim of this study was to investigate the discordance rates of eight known driver mutat...
Objective: Synchronous multiple ground-glass nodules (SM-GGNs) are a distinct entity of lung cancer ...
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry add...
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is hi...
IntroductionNo standard guidelines detailing recommendations for the selection and treatment for mul...
Background: Reported prevalence of driver gene mutations in non-small cell lung cancer (NSCLC) is hi...
Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is hi...
Background: Many studies have examined specific mutations in patients with resected lung adenocarcin...
Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variabl...
Background: KRAS, BRAF, EGFR and ALK-mutation testing is a prerequisite for non-small-cell lung canc...
Objective: Synchronous multiple ground-glass nodules (SM-GGNs) are a distinct entity of lung cancer ...
The prevalence of multiple lung cancers has been increasing recently. Molecular analysis of epiderma...
BackgroundMany studies have examined specific mutations in patients with resected lung adenocarcinom...
Objective: Previous studies have indicated that EGFR exon 19 deletions in non-small cell lung cancer...
Discovery of driver mutations in pulmonary adenocarcinoma has revolutionized the field of thoracic o...